Drugs / AOC 1020
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05747924 | Apr 2023 → Mar 2026 | facioscapulohumeral muscular dystrophy 1, facioscapulohumeral muscular dystrophy 2, fibromuscular dysplasia, frontometaphyseal dysplasia 2 +1 | Avidity Biosciences, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06547216 | Jul 2024 → Apr 2030 expected | facioscapulohumeral muscular dystrophy 1, facioscapulohumeral muscular dystrophy 2, fibromuscular dysplasia, frontometaphyseal dysplasia 2 +1 | Avidity Biosciences, Inc. | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07038200 | Jun 2025 → May 2028 expected | facioscapulohumeral muscular dystrophy 1, facioscapulohumeral muscular dystrophy 2 | Avidity Biosciences, Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-06-11 | Novartis Pharmaceuticals | Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint novartis.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AOC 1020 | “Del-brax (AOC 1020) will be administered 13 times” NCT07038200 ↗ |
| Known as | del-brax | “Del-brax (AOC 1020) will be administered 13 times” NCT07038200 ↗ |
| Route | Intravenous | “AOC 1020 will be administered via intravenous (IV) infusion” NCT05747924 ↗ |